GlassScriptPhysician profile
Steven B Kirschner
NPI 1447244579
$6,068.78
in general payments reported to CMS, 2019-2025
32 companies · $833 in 2025
The $833 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,157 · 2020: $185 · 2021: $536 · 2022: $1,440 · 2023: $918 · 2024: $1,000 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,583 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,583.45 |
| Education | $168.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,146.24 | 2019-2025 | |
| Janssen Biotech, INC. | $1,011.41 | 2019-2025 | Stelara, Tremfya, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $637.78 | 2019-2025 | Entyvio, Eohilia |
| E.R. Squibb & Sons, L.L.C. | $381.55 | 2022-2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $381.28 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $372.04 | 2019-2024 | Dificid, Zinplava |
| Celgene Corporation | $251.56 | 2021-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $227.84 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $177.23 | 2021-2025 | Ocaliva |
| Pfizer INC. | $166.03 | 2023-2025 | |
| Medtronic, INC. | $162.24 | 2022 | |
| Ardelyx, INC. | $160.90 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $157.61 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $148.77 | 2019-2025 | Linzess |
| Madrigal Pharmaceuticals | $77.10 | 2025 | Rezdiffra |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $69.90 | 2019 | |
| Lilly USA, LLC | $69.03 | 2023-2025 | Omvoh |
| Cumberland Pharmaceuticals, INC. | $54.02 | 2023 | Kristalose |
| Evoke Pharma, INC. | $52.43 | 2023 | Gimoti |
| Aimmune Therapeutics, INC. | $52.00 | 2024 | |
| Allergan, INC. | $44.67 | 2019 | |
| Novo Nordisk INC | $44.42 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $36.60 | 2023 | Dupixent |
| Alnylam Pharmaceuticals INC. | $29.38 | 2022 | |
| Capsovision, INC. | $24.79 | 2025 | Capsocam Plus |
| Shionogi INC | $23.96 | 2019 | |
| Braintree Laboratories, INC. | $21.07 | 2019 | |
| Mirum Pharmaceuticals, INC. | $20.81 | 2023 | Livmarli |
| Redhill Biopharma INC. | $20.66 | 2021 | |
| Organon LLC | $17.49 | 2025 | Hadlima |
| Nestle Healthcare Nutrition INC. | $14.08 | 2023 | |
| Alfasigma USA, INC. | $13.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Kirschner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.